When it comes to how the rapidly spreading coronavirus (COVID-19) is affecting people with vasculitis, medical experts agree there are more questions than answers—at least right now. To address that concern, the VF and the Vasculitis Patient Powered Research Network (VPPRN) have teamed up with partners in the Autoimmune Research Collaborative (ARC) to launch a new vasculitis and autoimmune COVID-19 patient study.
Thank you for your interest in the Vasculitis COVID-19 project. Your participation will help researchers, clinicians and other patients better understand how people with autoimmune and related conditions are dealing with COVID-19 / the novel coronavirus.
Participation involves completing several short surveys over the course of the next few months. Once you enroll, you will be asked to complete follow-up surveys that we will send to you every two weeks for the next 2 months and then again at 6 and 12 months. Each survey should take no more than 15 minutes of your time. We will send you an email with a web link when it is time to complete a survey.
To get started, please enter your email below and we will send you more information. including an invitation link that is unique to you.
Learn More About the Project
Capturing the Whole Picture:
- This project is a series of research surveys over time to help researchers and clinicians better understand coronavirus concerns of people with vasculitis and track respiratory illnesses across the United States and Canada. We will send a survey to you every two weeks for the next 2 months and then again at 6 and 12 months.
- Patients were involved in the design of the project and continue to serve on the project Steering Committee
April 29, 2020
Vasculitis COVID-19 Patient Project: Incredible Response to the Launch!
Thank You for Making Research Possible! We have had an incredible response after the launch of our Vasculitis COVID-19 Patient Project! Thank you for choosing to contribute to this important research. We are pleased to share current information we have collected to date. We will continue to share information including demographics, access to testing, and [...]